Novartis AG
New York Stock Exchange•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.Company Description
- CEO
- Dr. Vasant Narasimhan M.D.
- Full Time Employees
- 76,057
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Address
- Lichtstrasse 35 Basel Switzerland 4056
- IPO Date
- Nov 7, 1996
- CIK
- 0001114448
- Website
- novartis.com
- Similar Companies
- Business
- Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology, dermatology, respiratory, cardiovascular, renal, and metabolism medicine products. The Sandoz segment develops, manufactures, and markets finished dosage form medicines; active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties; and retail generics and anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran; and a clinical collaboration with Kura Oncology, Inc. to evaluate the combination of Tipifarnib and Alpelisib in patients with head and neck squamous cell carcinoma. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.
Company News
Swiss competition authority closes Novartis probe without consequences
NVS or LLY: Which Is the Better Value Stock Right Now?
5 Low-Leverage Stocks to Buy Buoyed by Impressive Tech Earnings
Looking for Stocks with Positive Earnings Momentum? Check Out These 2 Medical Names
Novartis: Value Continues To Build With Double-Digit Percentage Growth Products
Novartis: Best Performing Big Pharma Of Past 6 Months Still Looks A Solid Long-Term Bet
Generate:Biomedicines Announces Multi-Target Collaboration with Novartis to Discover and Develop Protein Therapeutics with Generative AI
Novartis CEO says FDA's extended approval of breast cancer drug is a 'landmark' for the firm
Novartis Wins FDA Approval of Kisqali for Early Breast Cancer
Novartis not joining the 'frenzy' of weight loss drugs, CEO says
Novartis not joining the 'frenzy' of weight loss drugs, CEO says
Novartis' Kisqali Lowers Risk of Breast Cancer Recurrence by 28%
FDA approves Novartis Kisqali® to reduce risk of recurrence in people with HR+/HER2- early breast cancer
Why Novartis (NVS) is a Top Momentum Stock for the Long-Term
Novartis Breast Cancer Drug Found To Cut Disease Recurrence
Novartis Kisqali® shows deepening benefit in new analysis, reducing the risk of recurrence by 28.5% in a broad population of patients with early breast cancer
Boost Your Portfolio's Health With These 4 Large-Cap Drug Stocks
This Novartis Analyst Is No Longer Bullish; Here Are Top Downgrades For Wednesday
Novartis to License VYGR's Capsid for Gene Therapy in Neurology
Goldman Sachs Shifts Stance On Novartis, Cites Lack Of Near-Term Catalysts